Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...
This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?
Barchart on MSN
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Learn more about whether Aurinia Pharmaceuticals Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback